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Available online 17 February 2018Introduction: Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow obstruction
and respiratory symptoms. While short course systemic GCs are prescribed in patients with acute COPD exacer-
bations, little is known of the risk of fractures with intermittent exposure to high-dose GC and the effect of prox-
ies of disease severity.
Methods: A case-control studywas conducted using the Danish National Hospital Discharge Registry (NHDR) be-
tween January 1996 to December 2011. Conditional logistics regression models were used to derive adjusted
odds ratios (OR) risk of fractures in subjects with COPD stratified by intermittent high-dose, and proxies of dis-
ease severity.
Result: A total of 635,536 cases and the same number of controls were identified (mean age 67.5 ± 13.8, 65% fe-
male). COPD patients with intermittent use of high average daily dose oral glucocorticoids did not have an in-
creased risk of any, osteoporotic, hip or clinically symptomatic vertebral fracture compared to non-COPD
patients (adj. OR 0.65; 95% CI: 0.50–0.86, 0.70; 95% CI: 0.70–0.99, 1.17; 95% CI: 0.59–2.32, 1.98; 95% CI:
0.59–6.65 respectively). We identified an elevated risk of osteoporotic fracture among patients who visited the
emergency unit (adj. OR 1.47; 95% CI 1.20–1.79) or were hospitalised in the past year for COPD (adj. OR 1.76;
95% CI 1.66–1.85). Current GC use among COPD patients was associated with an increased risk of osteoporotic,
hip and clinically symptomatic vertebral fractures compared to patients without COPD.
Conclusion: Intermittent high-dose GCswas not associatedwith an increased risk of any, osteoporotic, hip or clin-
ically symptomatic vertebral fractures in patients with COPD. Current GC usewas however associatedwith an in-
creased risk of hip and clinically symptomatic vertebral fractures. Therefore, emphasis on prophylactic treatment
of fracturesmay not be essential in patientswith COPD receiving intermittent dose ofGCs,whereas this should be
considered for high-dose long-term users with advanced COPD disease stage, postmenopausal women and men
over 40 years.





ences, Utrecht University, The1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by
persistent airflow obstruction and respiratory symptoms. It is projected
to be the third leading cause of morbidity and mortality by 2030 [1,2].
Pharmacologic management of stable COPD consists of short- and
long-acting bronchodilators, as well as inhaled and oral glucocorticoids
(GCs) [3]. In patients with acute COPD exacerbations, short courses of
239O.A. Oshagbemi et al. / Bone 110 (2018) 238–243systemic GCs are prescribed in order to reduce exacerbations, shorten
recovery time and reduce length of hospital stay [3]. Although not rec-
ommended by current international guidelines, a proportion of COPD
patients are chronically treated with low-dose oral GCs [4].
The detrimental effects of GCs on bone mineral density (BMD),
resulting in an increased (hip or vertebral) fracture risk, are well
established [5–9].While elevated fracture riskmay be caused by several
factors related to disease severity which negatively influences bone
structure, fracture risk remains elevated in patients using oral GCs
even after adjustment for proxy indicators of disease severity [10–12].
Consequently, GC use is included in risk prediction tools such as FRAX
[8] and international clinical guidelines on the prevention of GC-
induced osteoporosis [13].
Fracture risk associated with oral GC use increases rapidly, particu-
larly during thefirst 3months of treatment, and is partially independent
of a decreased BMD [14]. The increase in fracture risk is directly, and lin-
early, related to the daily, and possibly also to cumulative, dose of oral
GCs; yet the relative relationship between the two is not consistent
[5–7,15]. Thus clinicians suggest the use of intermittent dosing of GCs
to mitigate and manage GC-induced adverse effects, such as fractures
[16]. De Vries et al. evaluated the risk of fracture with intermittent use
of high-dose oral GC and found a small increased risk of osteoporotic
fractures among patients with various disease conditions requiring GC
use [7]. They defined intermittent high dose exposure as daily dose
≥15mgand cumulative dose exposure ≤1 g (for instance 30mgprednis-
olone equivalents per day for 2–4 weeks).
While the risk of fracture in patients with obstructive airways dis-
ease exposed to intermittent high-dose oral GC was examined by de
Vries et al. in a large British population, little is known of this risk in
COPD patients in other settings. Therefore the objective of the present
study was to investigate the effects of intermittent high-dose glucocor-
ticoid use on fracture risk in patients with COPD, the impact of proxy in-
dicators of disease severity and the effect of dose, compared to patients
without COPD.
2. Methods
2.1. Design and source population
A population-based case-control study was conducted using
healthcare records from Danish National databases. In Denmark, sepa-
rate registers of computerized medical records on all contacts to hospi-
tals and on the use of drugs can be linked for the entire population
(approximately 5.5 million inhabitants). The register was founded in
1977 and covers all inpatients contacts from 1977 to 1994, and from
1995 onwards also includes all outpatient visits to hospitals, outpatient
clinics and emergency rooms. After discharge, the physician enters the
reason for the contact according to the International Classification of
Diseased (ICD) system. The register has nationwide coverage of public
health facilities with an almost 100% completeness of recordings and a
high precision of diagnoses [17,18], particularly for fracture diagnoses
[6].
The DanishMedicines Agency keeps a nationwide prescription data-
base, the Register of Medicinal Product Statistics, with information on
prescriptions for refundable drugs. The database includes information
on the patient's civil registry number, the type and amount of drug pre-
scribed in accordance to the Anatomical Therapeutic Chemical (ATC)
classification system [2] and the date when the prescription was filled
by the patient. This permits an evaluation of the average daily dose
and cumulative exposure. All registers can be interconnected through
the use of the civil registry number that is assigned to all Danes [19].
2.2. Study population/outcome
Cases were identified as patients aged 45 years and older who had
sustained a fracture between January 1996 and December 2011.Fractures considered included a fracture of the hip (ICD10 code S72.0-
S72.2), clinical symptomatic vertebrae (S12, S22.0-S22.1, S32.0-S32.2,
S32.7, S32.8, T08), osteoporotic (defined as a fracture of the hip, clinical
symptomatic vertebrae, radius/ulna [S52] or humerus [S42.2-S42.4] ac-
cording to theWorld Health Organisation's (WHO) definition [20]. Any
fracture was determined by the following International Classification of
Diseases and Related Health Problems (ICD)-10 codes: S02, S12, S22,
S32, S42, S52, S62, S72, S82, S92, T02, T08, T10 and T12. For each case,
one control patient (who had not sustained a fracture) was matched
by gender and year of birth using incidence-density sampling [21].
The date of the first fracture defined the index date for cases, and con-
trols were assigned the index date of their matched cases.
2.3. Exposure
Presence of COPD before the index date was defined based on ICD-
10 code J43 or J44. Individuals without an ICD-10 code for COPD were
categorized as non-COPD patients and used as the reference category
in all analyses. Furthermore, among COPD patients we evaluated oral
glucocorticoid (GC) use before the index date. Based on the time since
the most recent GC dispensing from the index date patients was classi-
fied as current (1–91 days), recent (92–182), past (183–364 days) or
distant (over 364 days) users. For each current user, the cumulative
and average daily GC exposure was estimated. The average daily dose
was calculated by dividing the cumulative GC exposure by the treat-
ment time (i.e. the time between the first GC dispensing and the
index date). Intermittent high-dose of GC was defined as daily dose
≥15 mg and cumulative exposure b1 g [7]. This roughly corresponds to
30 mg prednisolone per day for 2–4 weeks. It is recommended that pa-
tients with COPD receive of 30mg of prednisolone for 7–14 days and no
longer that in the event of an exacerbation (ref). The cumulative dose
was calculated by adding up all previous GC dispensing using the de-
fined daily dosages (DDDs). The average daily dosewas calculated bydi-
viding the cumulative GC exposure by the treatment time (i.e. the time
between the first GC dispensing and the index date). GC exposure was
expressed as oral prednisolone equivalents.
2.4. Confounders
We considered the following potential confounders before the index
date: history of fracture, rheumatoid arthritis, inflammatory bowel dis-
ease (IBD), secondary osteoporosis (type 1 diabetes, hyperthyroidism,
hypogonadism and renal failure), dementia, type 2 diabetes mellitus,
cerebrovascular disease, pneumonia, malignancies (excluding non-
melanoma skin cancer) and gout. These potential confounders have
been related to fractures and COPD in previous studies [11,22]. Other
potential confounders included a dispensing in the six months before
the index date of the following drugs: inhaled cromoglycates, xanthine
derivates, bisphosphonates, vitamin D, calcium, raloxifene, strontium,
denosumab, calcitonin, parathyroid hormone, hormone replacement
therapy, antipsychotics, antidepressants, hypnotics/anxiolytics, anti-
convulsants, anti-parkinson drugs, antihypertensive drugs and proton
pump inhibitors. Proxy indicators of respiratory disease severity vari-
ables included a dispensing of inhaled corticosteroids, long-acting
beta-2 agonists, short-acting beta-2 agonists, long-acting anticholiner-
gics, short-acting anticholinergics, roflumilast, oxygen and the number
of accident & emergency registrations or hospitalisations for COPD in
the previous year [11].
2.5. Statistical analysis
Conditional logistic regression was used to estimate odds ratios
(ORs) for fracture risk (SAS 9.3). Final regression models were deter-
mined by stepwise backward elimination using a significance level of
0.05. Patients without COPD were the reference category, and among
COPD patients. Analyses were stratified by intermittent GC exposure,
240 O.A. Oshagbemi et al. / Bone 110 (2018) 238–243proxies of disease severity and average daily and cumulative dose expo-
sure for specific fracture sites. Proxies of disease severity considered in-
clude hospitalisation and emergency visits for COPD inprevious year. All
results were presented as ORwith corresponding 95% confidence inter-
vals (CIs).
3. Results
The study population consisted of 635,536 cases and the same num-
ber of controls. Baseline characteristics of the study participants are
shown in Table 1. The mean age at index date was 67.5 ± 13.8 and
65% were female. Approximately 18% of the cases (n = 113,553) and
15% of the controls (n = 97,460) used GCs in the six months before
the index date. There was a history of fracture among 24.4% of the
cases and 8% of the controls. A higher proportion of cases had used an-
ticonvulsants, hypnotics, anxiolytics and antidepressants in the six
months prior to index date. There were 38,013 (6%) patients with
COPD among the cases and 28,490 (4.5%) among controls.
Table 2 presents the adjusted fracture risk amongCOPDpatients cur-
rently exposed to oral glucocorticoid compared with patients without
COPD. COPD patients with intermittent use of high average daily dose
oral glucocorticoids did not have an increased risk of any, osteoporotic,
hip or clinically symptomatic vertebral fracture compared to patients






n % n %
Male sex 224,182 35.3 224,182 35.3
Mean age at index date (years, SD) 67.5 13.8 67.5 13.8
45–60 220,166 34.6 220,158 34.6
60–74 194,647 30.6 194,664 30.6
75+ 220,723 34.7 220,714 34.7
History of co-morbidities
Fracture 154,923 24.4 49,742 7.8
COPD 38,013 5.9 28,490 4.5
Pneumonia 21,106 3.3 15,771 2.5
Rheumatoid arthritis 12,245 1.9 9133 1.4
Inflammatory bowel disease 12,962 2.0 10,005 1.6
Secondary osteoporosis 32,275 5.1 25,041 3.9
Type 1 diabetes mellitus 13,897 2.2 8439 1.3
Type II diabetes mellitus 31,252 4.9 25,535 4.0
Hyperthyroidism 13,934 2.2 13,614 2.1
Hypogonadism 612 0.1 408 0.1
Renal failure 5570 0.9 3496 0.6
Dementia 16,572 2.6 9251 1.5
Cerebrovascular disease 54,999 8.7 41,511 6.5
Malignancies (excl. non-melanoma skin cancer) 71,393 11.2 62,780 9.9
Drug use within six months before index date
Oral glucocorticoids 113,553 17.9 97,460 15.3
Inhaled corticosteroids 21,550 3.4 19,236 3.0
Inhaled bronchodilators 44,096 6.9 37,105 5.8
Xanthine derivates 5427 0.9 4653 0.7
Bisphosphonates 16,941 2.7 10,211 1.6
Vitamin D 740 0.1 627 0.1
Calcium 8535 1.3 5777 0.9
Raloxifene 747 0.1 493 0.1
Hormone replacement therapy 45,381 7.1 55,626 8.8
Antipsychotics 31,258 4.9 20,080 3.2
Antidepressants 89,941 14.2 53,689 8.5
Hypnotics/anxiolytics 72,682 11.4 54,384 8.6
Anticonvulsants 21,443 3.4 10,456 1.7
Anti-Parkinson drugs 7030 1.11 3987 0.6
Antihypertensive drugs 228,310 35.9 227,776 35.8
Proton pump inhibitors 56,646 8.9 41,382 6.5
COPD related Emergency visit in past year 588 0.1 302 0.1
COPD related hospitalization in past year 9658 1.5 4252 0.7
Abbreviations: SD: standard deviation; COPD: chronic obstructive pulmonary disease.
a Data are number (%) of patients, unless stated otherwise.0.70–0.99, 1.17; 95%CI: 0.59–2.32, 1.98; 95%CI: 0.59–6.65 respectively).
However, the risk of osteoporotic fractures was significantly increased
among long time heavy users receiving a cumulative dose between 1
and 4.9 g (adj. OR: 1.46; 95% CI: 1.07–1.20), and the risk of hip fracture
increased among COPD patients with cumulative dose of 5.0–9.9 g (adj.
OR: 2.88; 95% CI: 1.27–6.57).
As a proxy for disease severity, we further stratified COPD patients
by patients with an emergency visit or hospitalisation for COPD in the
year prior to fracture (Table 3). We identified an elevated risk of osteo-
porotic fracture among patients who visited the emergency unit (adj.
OR 1.47; 95% CI 1.20–1.79) or were hospitalised in the past year for
COPD (adj. OR 1.76; 95% CI 1.66–1.85), as compared to patients without
COPD (Table 3). Similarly the risk of hip fracture was elevated in
hospitalised patients (adj. OR: 2.47; 95% CI: 2.26–2.70) and those who
visited the emergency unit (adj. OR: 2.13; 95% CI: 1.49–3.04) in the
past year, compared to non-COPD patients. The risk of clinically symp-
tomatic vertebral fractures showed a 3-fold increase among COPD pa-
tients following hospitalisation and emergency visit in the past year
when compared to patients without COPD. We also noticed an in-
creased risk of any fracture in patients with emergency visits or
hospitalisation for COPD.
The individual breakdown of average daily dose and cumulative
dose by fracture type among COPD patients, compared to non-COPD pa-
tients, is provided in Table 4. Current GC use among COPD patients was
associated with an increased risk of osteoporotic (adj. OR: 1.12; 95% CI:
1.05–1.20), hip (adj. OR: 1.23; 95% CI: 1.10–1.37) and clinically symp-
tomatic vertebral fractures (adj. OR: 1.87; 95% CI: 1.52–2.31) as com-
pared to patients without COPD except risk for any fracture. The risk
of hip and clinically symptomatic vertebral fractures increased with in-
creasing average daily doses, with patients exposed to 7.5–15 mg/day
having the greatest risk. Cumulative dose of 5.0–9.9 g was associated
with and increased risk of clinically symptomatic vertebral fractures
(adj. OR: 2.26; 95% CI: 1.52–3.35).
4. Discussion
In the current study, we found that exposure to intermittent high-
dose glucocorticoidwas not associatedwith an increased risk of any, os-
teoporotic, hip and clinically symptomatic vertebral fracture in COPD
patients compared to patients without COPD. Furthermore, we showed
that proxies of disease severity (hospitalisation and emergency visit for
COPD in the past year)were associatedwith an increased risk of any, os-
teoporotic, hip and clinically symptomatic vertebral fractures among
patients with COPD compared to patients without COPD.
This study extends previous knowledge from large population based
studies [5,6]. A cohort study by de Vries et al. [7], showed that intermit-
tent high-dose of glucocorticoid among patients with various diseases
requiring GC use was associated with a small increased risk of osteopo-
rotic and vertebral fractures, but no increased risk of hip fractures. In
their study, intermittent use of GC was defined as daily dose ≥15 mg
and cumulative exposure ≤1 g similar to our study. However, they
employed a cohort study design adjusting for covariates time-
dependently. This might explain the absence of the small increased
risk of osteoporotic and vertebral fractures with intermittent exposure
in our study. Another study among patients with COPD, found no in-
creased risk of vertebral fracture with intermittent use of systemic GC
[23]. The investigators defined intermittent use of GC as exposure to
prednisolone for an average of 4 months during the patient's lifetime
and the study population was comprised of men over 50 years. Addi-
tionally, intermittent use of GCs (daily dose ≥10 mg and cumulative
dose ≤1 g) did not change the BMD in patients with COPD [24] this
might explain our result. However, COPD patients exposed to continu-
ous GC use were 2.4 times more likely to have one or more vertebral
fracture [23].
In our study we defined emergency visits and hospitalisations for
COPD in the past year as proxies for disease severity. Patients with
Table 2







Clinical symptomatic vertebral Adj.
ORa,b
No COPD 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
COPD 1.06 (1.04–1.08) 1.03 (1.00–1.06) 1.08 (1.03–1.13) 1.31 (1.20–1.44)
By GC exposure
Current use 1.01 (0.96–1.06) 1.12 (1.05–1.20) 1.23(1.10–1.37) 1.87(1.52–2.31)
By average daily dose ≥ 15 mg/day (oral prednisone equivalents)
b1 g 0.65 (0.50–0.86) 0.70 (0.49–0.99) 1.17 (0.59–2.32) 1.98 (0.59–6.65)
1.0–4.9 g 1.14 (0.90–1.43) 1.46 (1.07–2.00) 1.61 (0.95–2.73) 2.43 (0.95–6.22)
5.0–9.9 g 1.36 (0.97–1.89) 1.40 (0.91–2.16) 2.88 (1.27–6.57) 0.93 (0.35–2.44)
≥10 g 1.07 (0.84–1.36) 1.19 (0.85–1.65) 1.59 (0.89–2.87) 1.25 (0.52–3.00)
Abbreviations: OR: odds ratio; GC: glucocorticoid; COPD: chronic obstructive pulmonary disease.
Current GC use: most recent GC dispensing with 1–91 days before index date.
a Values are the adjusted odds ratios (95% confidence interval).
b Adjusted for: prior fracture, history of pneumonia, inhaled corticosteroids, inhaled bronchodilators, antidepressants, hypnotics/anxiolytics, proton pump inhibitors, emergency visit
for COPD, hospitalisation for COPD, never, distant, past, and recent use of oral GCs.
241O.A. Oshagbemi et al. / Bone 110 (2018) 238–243COPD who were hospitalised or who visited the emergency unit in the
past year had an increased risk of hip, osteoporotic and clinically symp-
tomatic vertebral fractures. The severity of the disease may influence
the dose and duration of GC administered [9]. However, severity of pul-
monary disease was shown to be inversely proportional to BMD [11].
Our findings are in line with a population-based case-control study of
Danish patients with fractures exposed to corticosteroids (n =
124,655), reporting that overall fracture risk increasedwith the number
of days in which COPD patients were hospitalised [14]. While
hospitalisation was identified as an important proxy for disease se-
verity, the duration of disease has been found not to correlate with
fracture risk, as it does not reflect severity of disease [14]. Adjust-
ment for disease severity is limited in fracture studies [5,25,26]. In
our study we adjusted the primary analysis for proxies of disease
severity. Furthermore, studies have identified the importance of
disease severity on fracture risk in patients exposed to GC. Conse-
quently, adequate adjustments should be made when studying the
risk of fractures in COPD patients [11].
The present results are in line with a previous observational study,
which evaluated cumulative/daily dose and the risk of fractures using
the CPRD. The researchers found an increased risk of hip and vertebral
fractureswith higher daily doses of oral corticosteroids compared to pa-
tients using lower doses [10]. Our findings are also supported by a large
case-control study which reported an increased risk of hip fractures
with increasing average daily dose [10]. Vestergaard et al. [14] also re-
ported a dose-dependent increased risk of fractures, with the greatest
risk of hip fractures observed at a dose of ≥7.5 mg/day. Their study
was carried out in a subset of our population. In our study, an increased
risk of osteoporotic, clinically symptomatic vertebral and hip fractures
was observed at a dose of 7.5–15-mg/day compare to patients withoutTable 3
Adjusted risk of fracture among COPD patients stratified by proxies of disease severity compar
Any fracture Adj. ORa,b Osteoporotic frac
No COPD 1.00 (Reference) 1.00 (Reference)
COPD 1.05 (1.03–1.07) 1.03 (1.00–1.06)
Proxy indicators of disease
Emergency visit in past year for COPD
No
1.05 (1.03–1.07) 1.03 (1.00–1.06)
Yes 1.47 (1.27–1.71) 1.47 (1.20–1.79)
Hospitalisation in past year for COPD
No 1.07 (1.05–1.10) 1.06 (1.03–1.08)
Yes 1.66 (1.60–1.73) 1.76 (1.66–1.85)
Abbreviations: OR: odds ratio; GC: glucocorticoid; COPD: chronic obstructive pulmonary disea
Current GC use: most recent GC dispensing with 1–91 days before index date.
a Values are the adjusted odds ratios (95% confidence interval).
b Adjusted for previous fracture, history of pneumonia, inflammatory bowel disease, cerebro
notics/anxiolytics, proton pump inhibitors, hospitalizations for COPD, emergency visits for COPCOPD. The perceived increased risk of hip and osteoporotic fracture
with increasing cumulative dose seems to disappear after adjustment
for various confounders. However, the risk of GC related fractures was
reported to be strongly associatedwith daily dose thanwith cumulative
dose [6,27]. This may be due to misclassification of exposures to GC as
participant's exposures were ascertained by interviews and prone to re-
call bias. Researchers have emphasised the importance of daily dose
monitoring in patients exposed to GC, as risk of fracture have been
seen to return towards baseline following termination of GC therapy ir-
respective of cumulative dose [6].
Several mechanisms have been suggested for the possible relation-
ship between COPD and fracture. GC use has been associated to the re-
duction in bone mineral density and increased fracture risk via a
number of mechanisms which include inhibition of steroid synthesis
and inhibition over reduced calcium absorption from the gut and in-
creased loss of osteoclast, osteoblast, insulin like growth factor and col-
lagen [28,29]. It has been suggested that factors associated with COPD
itself may contribute to loss of bone mineral density [30,31]. Similarly,
low dietary calcium is correlated with low BMD and increase fracture
risk [25]. However, the risk of fracture among patients receiving oral
GCs is somewhat independent of decreased bone mineral density [7].
Damage to the micro-architecture of the trabecular bone has been at-
tributed to deformities of the vertebrae [32]. Furthermore, it is been re-
ported that cumulative exposure to GCs correlates with the degree of
the trabecular network of bones [33]. Furthermore, smoking remains a
major risk for COPD and may induce osteoporosis via various mecha-
nism which include the alteration of metabolism of calciotropic hor-
mone; dysregulation in the production, metabolism, and binding of
estradiol; alteredmetabolism of adrenal cortical hormone and bone an-
giogenesis [34].ed to patients without COPD.
ture Adj. ORa,b Hip fracture Adj. ORa,b Clinical symptomatic vertebral Adj. ORa,b
1.00 (Reference) 1.00 (Reference)
1.08 (1.03–1.13) 1.31(1.20–1.44)
1.08 (1.03–1.13) 1.31 (1.20–1.44)
2.13 (1.49–3.04) 3.15 (1.64–6.07)
1.11 (1.06–1.17) 1.35 (1.23–1.48)
2.47 (2.26–2.70) 3.08 (2.57–3.69)
se.
vascular disease, inhaled corticosteroids, inhaled bronchodilators, antidepressants, hyp-
D, and previous use of oral GCs.
Table 4







Clinical Symptomatic Vertebral Adj.
ORa,b
No COPD 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
COPD 1.06 (1.04–1.08) 1.03 (1.00–1.06) 1.08 (1.03–1.13) 1.31 (1.20–1.44)
By GC exposure
Current use 1.01 (0.96–1.06) 1.12 (1.05–1.20) 1.23(1.10–1.37) 1.87(1.52–2.31)
By average daily dose (oral prednisone equivalents)
b7.5 mg/day 0.98 (0.92–1.04) 1.08 (0.99–1.17) 1.16 (1.01–1.34) 1.53 (1.18–1.99)
7.5–15 mg/day 1.08 (0.99–1.17) 1.20 (1.07–1.34) 1.23 (1.02–1.47) 2.98 (2.05–4.33)
≥15 mg/day 1.01 (0.89–1.15) 1.15 (0.96–1.37) 1.66 (1.21–2.28) 1.55 (0.94–2.54)
By cumulative dose (oral prednisone equivalents)
b1.0 g 0.87 (0.77–0.99) 1.01 (0.86–1.18) 1.19 (0.89–1.59) 1.96 (1.10–3.46)
1.0–4.9 g 0.96 (0.89–1.04) 1.09 (0.98–1.22) 1.21 (1.01–1.45) 1.60 (1.15–2.24)
5.0–9.9 g 1.11 (1.00–1.22) 1.15 (1.02–1.31) 1.23 (0.99–1.53) 2.26 (1.52–3.35)
≥ 10 g 1.06 (0.98–1.15) 1.18 (1.06–1.31) 1.26 (1.06–1.51) 1.87 (1.33–2.64)
Abbreviations: OR: odds ratio; GC: glucocorticoid; COPD: chronic obstructive pulmonary disease.
Current GC use: most recent GC dispensing with 1–91 days before index date.
a Values are the adjusted odds ratios (95% confidence interval).
b Adjusted for previous fracture, history of pneumonia, inhaled corticosteroids, inhaled bronchodilators, antidepressants, hypnotics/anxiolytics, proton pump inhibitors, hospitalizations
for COPD, emergency visits for COPD, and previous use of oral GCs.
242 O.A. Oshagbemi et al. / Bone 110 (2018) 238–243The main strength of our study was the large sample size among
cases and controls. This was possible because our study was conducted
using the Danish National database with roughly 5 million anonymised
patient records fromacrossDenmark [17].We considered hospitalisation
and emergency visit in the past year as proxies for disease severity [14].
Althoughwe adjusted our analyses for these proxies this might not have
completely corrected for the severity of the disease. Our limitations in-
cluded the lack of information on smoking, alcohol use, inflammatory
markers, muscle mass or strength and BMD as such we could not adjust
for these potential confounders in our analysis. There is also the problem
of diagnosis of vertebral fracture, which ismostly done by clinical and ra-
diological assessment, as such asymptomatic vertebral fractures aremost
likely to go undetected [6].We could not independently confirm the pre-
dictive values of cases diagnosed with fractures by the general practi-
tioner. Although, a high positive predictive value (93%) of diagnosis of
fractures has been reported in the Danish database [26]. This limits the
possibility of non-differential misclassification. As with most observa-
tional studies, we could not rule out the possibility of misclassification
of exposure to GCs. Information on potential treatment received prior
to entry into the Danish national database was also not available. We
also lacked information on severity of COPD as such there may be con-
founding by indication [9].
In conclusion, intermittent high-dose GCs was not associated with
an increased risk of any, osteoporotic, hip or clinically significant verte-
bral fractures in patients with COPD. Current GC use however was asso-
ciatedwith an increased risk of hip and clinically symptomatic vertebral
fracture. It is important to also note that COPD alone increases the risk of
fracture compared to those without COPD, especially among patients
with history of hospitalisation or emergency roomvisit for COPD. There-
fore, emphasis on prophylactic treatment of fracturesmay not be essen-
tial in patients with COPD receiving intermittent dose of GCs, whereas
this should be considered for high-dose long-term users with advanced
COPD disease stage, postmenopausal women and men over 40 years.
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